Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Respiratory microbiome changes after starting Orkambi in cystic fibrosis
NL-OMON45428Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Amsterdam University Medical Center. Primary endpoints: Bacterial sequences, Metabolic profiles and 1 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45428.